Chelsea’s Hope Started a Volunteer Program

/by

We’re looking for the best kind of people: volunteers. Join a network dedicated to curing Lafora disease.

We’re excited to announce the launch of our volunteer program!! Please check out our new volunteer page and fill out the volunteer interest form to join the volunteer network.

You can make a difference with your skills and talents when you sign up to volunteer with Chelsea’s Hope! Partner with us to improve the lives of those affected by Lafora disease. You don’t need volunteer or work experience, but you do need passion and dedication.

Please spread the word that Chelsea’s Hope started a volunteer program! Share it with your friends and family, because we can do more together.
Volunteer with Chelsea’s Hope

Update on Myozyme and Lumizyme drugs from Sanofi for Lafora Disease treatment

/by
Chelsea’s Hope continues to champion the development of effective Lafora disease (LD) therapeutics in both the research community and with interested companies. One recurring question is whether currently used therapeutics for other glycogen storage diseases could be used in LD. As you know, this would greatly benefit our community, allowing rapid therapeutic adoption.

Because of the similarities between LD and Pompe disease, there has been considerable interest if Myozyme and Lumizyme (from Sanofi Pharmaceuticals) could be effective in LD. The diseases are similar in the accumulation of aberrant glycogen, but different in where the aberrant glycogen is located. In LD, Lafora Bodies (LBs) are in the cytoplasm of cells, whereas in Pompe, the aberrant glycogen is in lysosomes. Because of the strong connections between Chelsea’s Hope and the LD research community, several groups have explored this possibility. Unfortunately, they have found that Myozyme does not effectively target brain LBs in LD mouse models. Given the similarities between Myozyme and Lumizyme, the results also strongly suggest that Lumizyme would be ineffective for LD. These data will be published in a peer-reviewed journal in the coming months. As a service to the community, Chelsea’s Hope wanted to be sure these data were communicated as soon as possible.

While disappointing, these results help to focus our efforts on the multiple therapeutic strategies which have shown to be effective in pre-clinical LD models. Multiple therapeutics were presented at the recent LD meeting, including cytoplasmic targeted enzymes and substrate reduction strategies. We continue to advocate for these to be developed and tested with maximal speed.

Shining a light on Lafora disease for Rare Disease Day 2023

/by

We will show our stripes for Lafora disease on 2023 Rare Disease Day.

SACRAMENTO, Calif. – February 27, 2023 – Chelsea’s Hope Lafora Children Research Fund, a 501(c)(3) nonprofit organization, wants to share stories of Lafora disease patients like Alexis Rodriguez to raise awareness about the ultra-rare epilepsy.

Lafora Disease is a degenerative neurological condition affecting children. It is a genetic condition in which patients cannot maintain a normal glycogen concentration, resulting in a toxic accumulation of glycogen, or Lafora Bodies, in the heart, spine, and brain. Symptoms include ataxia, childhood dementia, cognitive decline, and difficulty speaking, walking, and eating.

Alexis Rodriguez’s first symptom was a seizure. Now 19, she was a healthy and bright student before the onset of her symptoms. She played the violin, was an avid reader, and was a swimmer on her high school team. Her dream was to become a registered nurse.

Over the past three years, Alexis experienced frequent seizures, could no longer attend school in person and lost her ability to walk and talk. Now, she relies on a customized wheelchair, feeding tube, and full-time care from her single mother, AC, godmother, and nurse.

“Lafora robs the children of the right to live,” says AC.

Alexis’s story is similar to other Lafora patients. Children first show symptoms in their early teens and typically die within 10 years. There are an estimated 200 Lafora patients worldwide. Lafora Disease is terminal; there is no cure. But Rare Disease Day provides hope and a platform to share these stories. Today is the day to help raise awareness!

Alexis’s doctors have applied for FDA approval for the emergency use of a medication to target the glycogen buildup in her muscles. Unfortunately, her insurance company will not cover the cost of this treatment, even though it could slow down the pace of this disease and give Alexis a fighting chance. Her mother started Angels for Alexis in December 2022. To help her family access the treatment, visit https://chelseashope.org/donate/ and specify that you’re donating to “TEAM ALEXIS” for a tax-deductible donation. Follow @angelsforalexis on Instagram for updates.


###

Chelsea’s Hope was created in 2007 when Linda Gerber and a small group of dedicated friends developed a website to share her daughter Chelsea’s story. Today, Chelsea’s Hope Lafora Children Research Fund aims to improve the lives of those affected by Lafora Disease by raising awareness, connecting families, and accelerating research. Follow Chelsea’s Hope across social media @chelseashopelaforacure and find more information online or donate to help accelerate research at chelseashope.org.

Contact info@chelseashope.org for press inquiries.

 

Read press release

New article about Lafora disease

/by
 New from Dr. Jordi Duran! It’s a review on how the accumulation of glycogen in astrocytes, glial cells in the central nervous system, contribute to Lafora disease and other neurodegenerative conditions.